Global Newsroom | CSL
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination. Sep 30, 2024 - Head-to-head data, presented at OPTIONS XII for the Control of Influenza Conference, demonstrates advantage of sa-mRNA over conventional mRNA in duration of immune response; Results highlight CSL...
News Releases | CSL
Nov 2, 2022 · For more information visit www.csl.com. Media Contacts: Greg Healy Email: Greg.Healy@cslbehring.com +1 610 906 4564 In Australia: Jimmy Baker Email: Jimmy.Baker@csl.com.au +61 450 909 211 Kim O'Donohue Email: Kim.ODonohue@csl.com.au +61 449 884 603. In Europe: Jasmin Joller Email: jasmin.joller@cslbehring.com. SOURCE CSL.
CSL's Garadacimab, a First-in-Class Factor XIIa Inhibitor, Receives …
Dec 14, 2023 · These regulatory milestones bring CSL one step closer to delivering on our promise to patients with a first-in-class recombinant monoclonal antibody for people living with HAE, a community CSL has been serving for over 40 years, in the U.S. and European Union.
CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial ...
KING OF PRUSSIA, Pa., Feb. 11, 2024 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced top-line results from the Phase 3 AEGIS-II trial evaluating the efficacy and safety of CSL112 (apolipoprotein A-I [human]) compared to placebo in reducing the risk of major adverse cardiovascular events (MACE) in patients following an acute myocardial infarction (AMI).
CSL Announces Closing of Global Collaboration and Licensing …
Dec 12, 2022 · CSL to access late-stage next-generation mRNA platform technology, enabling development of vaccines for COVID-19, influenza, multi-pathogen pandemic preparedness and other respiratory pathogens...
CSL announces carbon emissions reduction targets
MELBOURNE, Australia, Aug. 16, 2022 / PRNewswire / -- CSL Limited (ASX: CSL) Today, CSL advances its vision for a more sustainable future by setting new, tangible targets for carbon emissions reductions. As part of the company's broader sustainability strategy to build a more sustainable future for employees, communities, patients and donors ...
News Releases - CSL
Jun 6, 2022 · The expanded manufacturing facility and new pre-filled syringe line will allow Seqirus to increase its capacity to supply the U.S. market with FLUCELVAX® QUADRIVALENT (Influenza Vaccine), the first and only cell-based quadrivalent influenza vaccine in the U.S. for individuals six months of age and older. 1 “According to the World Health Organization (WHO), seasonal influenza can lead to up ...
News Releases - CSL
Jun 24, 2022 · First doses were rolled out in March 2021, with over 40 million doses released as of June 2022. In 2020, CSL worked with the University of Queensland in the early stages of its UQ-CSL v451 COVID-19 vaccine candidate. A Phase I clinical trial showed that the vaccine elicited a robust response towards the virus and had a strong safety profile.
CSL Vifor and Travere Therapeutics Announce Swissmedic …
2 days ago · Temporary marketing authorization is based on statistically significant and clinically meaningful results from the phase-III PROTECT trial. ST. GALLEN, Switzerland and SAN DIEGO, Oct. 17, 2024 /PRNewswire/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that Swissmedic has granted temporary marketing authorization for FILSPARI for the treatment of adults with ...
News Releases | CSL
Oct 26, 2022 · Global Newsroom. News Releases. CSL enters into Strategic Option and License Agreement with Translational Sciences. Option to acquire exclusive, global license to enhanced thrombus dissolving drug candidate TS23. KING OF PRUSSIA, PA – 26 October 2022 Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY), today announced the company has ...